4.8 Article

The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 128, 期 7, 页码 2802-2818

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI92981

关键词

-

资金

  1. Ministerio de Economia y Competitividad (MINECO) [PLE-2009-0110, SAF2010-15106, SAF2013-44857-R, SAF2016-75442-R]
  2. Fundacion Sandra Ibarra
  3. Fundacion Asociacion Espanola Contra el Cancer [AECC CI13131229]
  4. Instituto de Salud Carlos III [RTICC RD06/0014/1012]
  5. European Union [602587]
  6. Fundacion Ramon Areces
  7. Banco de Santander
  8. MINECO

向作者/读者索取更多资源

NOTCH1 is a prevalent signaling pathway in T cell acute lymphoblastic leukemia (T-ALL), but crucial NOTCH1 downstream signals and target genes contributing to T-ALL pathogenesis cannot be retrospectively analyzed in patients and thus remain ill defined. This information is clinically relevant, as initiating lesions that lead to cell transformation and leukemia-initiating cell (LIC) activity are promising therapeutic targets against the major hurdle of T-ALL relapse. Here, we describe the generation in vivo of a human T cell leukemia that recapitulates T-ALL in patients, which arises de novo in immunodeficient mice reconstituted with human hematopoietic progenitors ectopically expressing active NOTCH1. This T-ALL model allowed us to identify CD44 as a direct NOTCH1 transcriptional target and to recognize CD44 overexpression as an early hallmark of preleukemic cells that engraft the BM and finally develop a clonal transplantable T-ALL that infiltrates lymphoid organs and brain. Notably, CD44 is shown to support crucial BM niche interactions necessary for LIC activity of human T-ALL xenografts and disease progression, highlighting the importance of the NOTCH1/CD44 axis in T-ALL pathogenesis. The observed therapeutic benefit of anti-CD44 antibody administration in xenotransplanted mice holds great promise for therapeutic purposes against T-ALL relapse.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据